Serious adverse events ‐ not reported · farmworkers, soldiers, and people in endemic areas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · farmworkers, soldiers, and people in endemic areas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · farmworkers, soldiers, and people in endemic areas
It is very uncertain whether summary of findings table ‐ Antibiotics changes non‐serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse event ‐ not reported · people with leptospirosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Perioperative mortality · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Hepatic encephalopathy · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin probably leads to lower hepatic encephalopathy ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).
1 finding from 1 review
Blood ammonia measured in μg/mL at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
Number Connection Test A, assessed using: seconds (1 trial) or Z‐score (1 trial) at trial end · prevention and treatment of hepatic encephalopathy in people with cirrhosis
1 finding from 1 review
All‐cause mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes all‐cause mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Liver‐related mortality · people with chronic liver diseases
It is very uncertain whether vitamin D changes liver‐related mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review